biostudies-literaturePich OCancer Research UKAgence Nationale de la RechercheThe Myelodysplastic Syndromes FoundationNational Institutes of HealthHORIZON EUROPE European Innovation CouncilRoyal SocietyThe Royal SocietyEuropean Molecular Biology OrganizationSwiss National Science FoundationEuropean Research CouncilKay Kendall Leukaemia FundHorizon 2020 Framework ProgrammeMedical Research CouncilEPAEuropean Hematology AssociationNCI NIH HHSEdward P Evans MDS FoundationLeukaemia UKDamon Runyon Cancer Research FoundationWellcome TrustH2020 Marie Skłodowska-Curie Actions1594-1608https://www.ebi.ac.uk/biostudies/studies/S-EPMC12021423biostudies-literatureUnknown392(16)<h4>Background</h4>Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencies can be detected in tumors, a phenomenon we term tumor-infiltrating clonal hematopoiesis (TI-CH). The frequency of TI-CH and its effect on tumor evolution are unclear.<h4>Methods</h4>We characterized CHIP and TI-CH in 421 patients with early-stage non-small-cell lung cancer (NSCLC) from the TRACERx study and in 49,351 patients from the MSK-IMPACT pan-cancer cohort. We studied the association of TI-CH with survival and disease recurrence and evaluated the functional effect of <i>TET2</i>-mutant CHIP on the biologic features of lung tumors.<h4>Results</h4>Among patients with NSCThe New England journal of medicineTumor-Infiltrating Clonal Hematopoiesis.PMC12021423835297CC2041, CC2027, CC2085, FC001070P30 CA008748CC2041CC2085EBSTF-2022/100044838540RF\ERE\210216212304/Z/18/ZRSRP\R\210001TMAG-3_209224101024529KKL1397RG112ALTF 831-202CA254838-01WT209199/Z/17/ZANR-23-IAIHU-0002834692CC2097890933EP/Z534298/1R35 CA263816MR/N013867/1101068227CA263816RCCCDF- Nov21\100005P50 CA2548382021/JGF/002EP-D-18-001CC2027Bailey CSwanton CO'Sullivan JJoyce JAWack AHarris SKIliakis CSDownward JLo Celso CQuezada SAClark SAMead AJHuerga Encabo HMalanchi IZagorulya MPich OZaidi RBonnet DScott REnfield KSSThol KPearce DRRane JKBerger MFStonestrom AJPapazoglou DAlvarez-Prado AFHackshaw ABrierley CKMagness AGrey WPapaemmanuil ERowan ADijkstra KKPospori CGronroos EGreen MSlama RBola SKHynds REJamal-Hanjani MAnastasiou PBarbe VHoxha EZaccaria SBernard EPeggs KSRudin CMfalseTumor-Infiltrating Clonal Hematopoiesis.<h4>Background</h4>Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencies can be detected in tumors, a phenomenon we term tumor-infiltrating clonal hematopoiesis (TI-CH). The frequency of TI-CH and its effect on tumor evolution are unclear.<h4>Methods</h4>We characterized CHIP and TI-CH in 421 patients with early-stage non-small-cell lung cancer (NSCLC) from the TRACERx study and in 49,351 patients from the MSK-IMPACT pan-cancer cohort. We studied the association of TI-CH with survival and disease recurrence and evaluated the functional effect of <i>TET2</i>-mutant CHIP on the biologic features of lung tumors.<h4>Results</h4>Among patients with NSC2025-01-01T00:00:00Z2025 Apr2026-04-08T19:50:04.428Z2025-07-01T03:05:06.835ZS-EPMC120214234026742510.1056/NEJMoa2413361